

Learner Notification

MED Learning Group

Immune Challenges in Cancer: First-Line IO Therapy of Advanced Non-Small Cell Lung Cancer

August 15, 2023 – August 15, 2024

Online

Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Evaluate recent immune checkpoint inhibitor (ICI) monotherapy trials data in patients with advanced NSCLC without targetable mutations.
2. Examine clinical findings for the combination of ICI and chemotherapy in the management of patients with advanced NSCLC.
3. Describe the recognition and management of immune-related adverse events in patients with advanced NSCLC treated with immunotherapy.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Lauren	Bartunek	NA
Millie	Das	Eurofins: Consultant. She also provides contracted research for Genentech, Merck, CellSight Technologies, Novartis, Varian Medical Systems, Verily, United Therapeutics, Abbvie, and Celgene. Dr. Das also receives fees for Non-CME/CE services directly from Sanofi/Genzyme, BeiGene, Regeneron, Astra Zeneca, and Janssen
Matthew	Frese	NA
Christina	Gallo	NA
Heather	Gee	NA
Nicole	Longo	NA
Aimee	Meissner	NA
Anita	Misra-Press	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com